Written by PX1 Research Team
PX1 chemists and research educators with hands-on experience in US-based peptide manufacturing, HPLC / mass-spectrometry lot testing, and endotoxin QC. All content is citation-backed and peer-reviewed for accuracy.
The Complete Guide to Retatrutide Research in 2026
Research Guide
Reviewed By
PX1 QC — Analytical Chemistry Team
Every article is reviewed by PX1's in-house analytical team for accuracy on mechanism, dosing ranges reported in the literature, and lab-handling guidance. We do not publish clinical or medical advice.
Quick answer
Retatrutide (LY-3437943) is a GLP-1 / GIP / glucagon triple agonist. Mechanism, Phase 2 data, handling, and purity considerations for research.
Key takeaways
- GLP-1 agonism: slows gastric emptying, promotes satiety, augments glucose-dependent insulin secretion.
- GIP agonism: potentiates postprandial insulin release and appears to modulate adipose tissue.
- Glucagon agonism: increases resting energy expenditure — the pathway most closely associated with retatrutide's fat-loss magnitude.
- HPLC purity ≥99% with chromatogram
What Retatrutide is
Retatrutide (also written LY-3437943, and often referred to as "reta") is a triple-agonist synthetic peptide developed by Eli Lilly. It simultaneously activates three receptors implicated in metabolic regulation: GLP-1, GIP, and glucagon. That third pathway — glucagon receptor activation — is what separates retatrutide from tirzepatide (dual GLP-1/GIP) and semaglutide (single GLP-1) in the research literature.
In Phase 2 studies at 48 weeks, participants receiving 12 mg weekly retatrutide showed mean weight reduction of roughly 24% — the largest weight loss ever reported for an incretin-class investigational drug at that time. Phase 3 trials (TRIUMPH program) are ongoing.
Mechanism of action
Retatrutide is a 39-amino-acid peptide with a fatty acid side chain that binds serum albumin, extending its half-life to approximately 6 days — supporting once-weekly dosing schedules in trials. Its receptor profile:
- GLP-1 agonism: slows gastric emptying, promotes satiety, augments glucose-dependent insulin secretion.
- GIP agonism: potentiates postprandial insulin release and appears to modulate adipose tissue.
- Glucagon agonism: increases resting energy expenditure — the pathway most closely associated with retatrutide's fat-loss magnitude.
Research highlights
Published Phase 2 data (NEJM, 2023) reported dose-dependent reductions in body weight, hepatic steatosis, and HbA1c in adults with obesity and type 2 diabetes. Adverse events were primarily gastrointestinal — nausea, diarrhea, and constipation — largely consistent with GLP-1 class effects and typically titration-responsive.
Laboratory handling
Retatrutide is supplied lyophilized and is stable at room temperature in sealed vials for 18–24 months. Standard reconstitution research protocols use bacteriostatic water; once reconstituted, storage under refrigeration is recommended and the solution is typically used within 30 days.
Purity and identity verification
Every PX1 retatrutide lot ships with a lot-specific Certificate of Analysis containing:
- HPLC purity ≥99% with chromatogram
- LC-MS or MALDI-TOF identity confirmation
- Endotoxin (LAL) and sterility results
- Residual solvents and Karl Fischer moisture
View current retatrutide lot documentation at /purity-reports.
Sourcing considerations
Retatrutide is not FDA-approved and is not available by prescription in the United States. Any product supplied for research must be labeled as such. When evaluating a source, verify three things: (1) domestic manufacturing or full import documentation, (2) lot-specific COA with chromatogram, (3) intact vials with correct fill volume and appearance (white to off-white lyophilized cake, no discoloration).
Related research reading
- Retatrutide vs Tirzepatide vs Semaglutide
- CagriSema vs Retatrutide
- Product: browse Retatrutide at PX1.
Research use only. Not for human or veterinary use.